Reuters logo
BRIEF-Five Prime Therapeutics plans to initiate a global pivotal trial of FPA144 in 2018
July 17, 2017 / 8:23 PM / 2 months ago

BRIEF-Five Prime Therapeutics plans to initiate a global pivotal trial of FPA144 in 2018

July 17 (Reuters) - Five Prime Therapeutics Inc

* Five prime Therapeutics initiates patient dosing in phase 1 clinical safety trial evaluating FPA144 in gastric cancer in Japan in preparation for future global late-stage development

* Plans to initiate a global pivotal trial of FPA144 in 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below